Page last updated: 2024-08-25

rosiglitazone and alpha-Lipoprotein Deficiency Disease, Familial

rosiglitazone has been researched along with alpha-Lipoprotein Deficiency Disease, Familial in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE	1

Other Studies

1 other study(ies) available for rosiglitazone and alpha-Lipoprotein Deficiency Disease, Familial

Article	Year
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Molecular & cellular proteomics : MCP, 2016, Volume: 15, Issue:3 Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Proteomics; Risk Factors; Rosiglitazone; Thiazolidinediones	2016

Article

Year

Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.

Molecular & cellular proteomics : MCP, 2016, Volume: 15, Issue:3

Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Proteomics; Risk Factors; Rosiglitazone; Thiazolidinediones

2016